Top

Published in:

Open Access 01-08-2016 | Original Article

Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)

Authors: E. J. Reuvekamp, B. F. Bulten, MD, A. A. Nieuwenhuis, M. R. A. Meekes, A. F. J. de Haan, J. Tol, MD, PhD, A. H. E. M. Maas, MD, PhD, S. E. Elias-Smale, MD, PhD, L. F. de Geus-Oei, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 4/2016

Abstract

Background

Trastuzumab is successfully used for the treatment of HER2-positive breast cancer. Because of its association with cardiotoxicity, LVEF is monitored by MUGA, though this is a relatively late measure of cardiac function. Diastolic dysfunction (DD) is believed to be an early predictor of cardiac impairment. We evaluate the merit of MUGA-derived diastolic function parameters in the early detection of trastuzumab-induced cardiotoxicity (TIC).

Methods and Results

77 trastuzumab-treated patients with normal baseline systolic and diastolic function were retrospectively selected (n = 77). All serial MUGA examinations were re-analyzed for systolic and diastolic function parameters. 36 patients (47%) developed SD and 45 patients (58%) DD during treatment. Both systolic and diastolic parameters significantly decreased. Of the patients with SD, 24 (67%) also developed DD. DD developed prior to systolic impairment in 54% of cases, in 42% vice versa, while time to occurrence did not differ significantly (P = .52). This also applied to the subgroup of advanced stage breast cancer patients (P = .1).

Conclusions

Trastzumab-induced SD and DD can be detected by MUGA. An impairment of MUGA-derived diastolic parameters does not occur prior to SD and therefore cannot be used as earlier predictors of TIC.

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 2007;7:153.CrossRefPubMedPubMedCentral

Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013;31:4222-8.CrossRefPubMedPubMedCentral

Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: Addressing the unresolved issues. Circulation 2012;126:2749-63.CrossRefPubMedPubMedCentral

Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J 2013;34:1102-11.CrossRefPubMed

Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat 2011;130:845-54.CrossRefPubMed

Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 1987;9:184-8.CrossRefPubMed

Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al. Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92-8.CrossRefPubMed

Lange SA, Ebner B, Wess A, Kogel M, Gajda M, Hitschold T, et al. Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy. Clin Res Cardiol 2012;101:415-26.CrossRefPubMed

Dores H, Abecasis J, Correia MJ, Gandara F, Fonseca C, Azevedo J, et al. Detection of early sub-clinical trastuzumab-induced cardiotoxicity in breast cancer patients. Arq Bras Cardiol 2013;100:328-32.PubMed

10.

Mitra D, Basu S. Equilibrium radionuclide angiocardiography: Its usefulness in current practice and potential future applications. World J Radiol 2012;4:421-30.CrossRefPubMedPubMedCentral

11.

Corbett JR, Akinboboye OO, Bacharach SL, Borer JS, Botvinick EH, DePuey EG, et al. Equilibrium radionuclide angiocardiography. J Nucl Cardiol 2006;13:e56-79.CrossRefPubMed

12.

Jovin IS, Ebisu K, Liu YH, Finta LA, Oprea AD, Brandt CA, et al. Left ventricular ejection fraction and left ventricular end-diastolic volume in patients with diastolic dysfunction. Congest Heart Fail 2013;19:130-4.CrossRefPubMed

13.

Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003;10:132-9.CrossRefPubMed

14.

Goeman JJ, Solari A. Multiple hypothesis testing in genomics. Stat Med 2014;33:1946-78.CrossRefPubMed

15.

Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncol 2009;10:391-9.CrossRefPubMed

16.

Suzuki J, Yanagisawa A, Shigeyama T, Tsubota J, Yasumura T, Shimoyama K, et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angiology 1999;50:37-45.CrossRefPubMed

17.

Ganz WI, Sridhar KS, Forness TJ. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate. Am J Clin Oncol 1993;16:109-12.CrossRefPubMed

18.

Wang J, Khoury DS, Yue Y, Torre-Amione G, Nagueh SF. Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. Eur Heart J 2008;29:1283-9.CrossRefPubMed

19.

Tocchetti CG, Ragone G, Coppola C, Rea D, Piscopo G, Scala S, et al. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: An actual challenge. Eur J Heart Fail 2012;14:130-7.CrossRefPubMed

20.

Markman TM, Markman M. Cardiotoxicity of antineoplastic agents: What is the present and future role for imaging? Curr Oncol Rep 2014;16:396.CrossRefPubMed

21.

Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910-6.CrossRefPubMed

22.

Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol 2013;20:443-64.CrossRefPubMed

23.

Wood PW, Choy JB, Nanda NC, Becher H. Left ventricular ejection fraction and volumes: It depends on the imaging method. Echocardiography 2014;31:87-100.CrossRefPubMed

24.

Muntinga HJ, van den Berg F, Knol HR, Niemeyer MG, Blanksma PK, Louwes H, et al. Normal values and reproducibility of left ventricular filling parameters by radionuclide angiography. Int J Card Imag 1997;13:165-71.CrossRef

25.

Bulten BF, Mavinkurve-Groothuis AM, de Geus-Oei LF, de Haan AF, de Korte CL, Bellersen L, et al. Early myocardial deformation abnormalities in breast cancer survivors. Breast Cancer Res Treat 2014;146:127-35.CrossRefPubMed

26.

Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J 2009;158:294-301.CrossRefPubMed

27.

Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57:2263-70.CrossRefPubMed

28.

Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26:493-8.CrossRefPubMed

29.

Carrio I. Cardiac neurotransmission imaging. J Nucl Med 2001;42:1062-76.PubMed

30.

Stokkel MP, de Wit-van der Veen LJ, Boekhout A. I-123-MIBG myocardial imaging in trastuzumab-based cardiotoxicity: The first experience. Nucl Med Commun 2013;34:19-24.CrossRefPubMed

31.

Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, et al. Role of three-dimensional echocardiography in breast cancer: Comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010;28:3429-36.CrossRefPubMed

32.

Martin M, Esteva FJ, Alba E, Khandheria B, Perez-Isla L, Garcia-Saenz JA, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations. Oncologist 2009;14:1-11.CrossRefPubMed

Title: Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)
Authors: E. J. Reuvekamp
B. F. Bulten, MD
A. A. Nieuwenhuis
M. R. A. Meekes
A. F. J. de Haan
J. Tol, MD, PhD
A. H. E. M. Maas, MD, PhD
S. E. Elias-Smale, MD, PhD
L. F. de Geus-Oei, MD, PhD
Publication date: 01-08-2016
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 4/2016
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-015-0164-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)

Abstract

Background

Methods and Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2016

The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy

Evaluation of ECG-gated [11C]acetate PET for measuring left ventricular volumes, mass, and myocardial external efficiency

Nuclear Cardiology in the Literature: A selection of recent, original research papers

Ventricular arrhythmia originating from scar border tissue during dobutamine myocardial perfusion gated SPECT on CZT camera

Using advanced technology to reduce the dose of SPECT MPI radiation

Does clopidogrel affect the efficacy of myocardial perfusion imaging?